BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
TAIPEI, July 28, 2026 /PRNewswire/ -- Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) drug ...
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in ...
HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
An implanted device (typically used to treat pain) that stimulates the thoracic spinal cord and sympathetic ganglia was coupled with accelerometers that detect changes in body position. With this ...
- Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol - - FDA agreed that a single pivotal Phase 3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results